Integrins and bone metastasis: Integrating tumor cell and stromal cell interactions

被引:119
作者
Schneider, Jochen G. [2 ,3 ]
Amend, Sarah R. [1 ]
Weilbaecher, Katherine N. [1 ]
机构
[1] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA
[2] Univ Wuetzburg, Inst Clin Biochem & Pathobiochem, Wuetzburg, Germany
[3] Univ Luxembourg, LCSB, Luxembourg, Luxembourg
关键词
Integrins; Bone metastasis; Osteoclasts; Endothelium; Platelets; Cancer therapy; ENDOTHELIAL GROWTH-FACTOR; COLONY-STIMULATING FACTOR; PROTEASE-ACTIVATED RECEPTORS; INDUCED PLATELET-AGGREGATION; BREAST-CANCER METASTASIS; HUMAN PROSTATE-CANCER; VON-WILLEBRAND-FACTOR; ANGIOGENESIS IN-VIVO; HEMATOPOIETIC STEM; ALPHA(V)BETA(3) INTEGRIN;
D O I
10.1016/j.bone.2010.09.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Integrins on both tumor cells and the supporting host stromal cells in bone (osteoclasts, new blood vessels, inflammatory cells, platelets and bone marrow stromal cells) play key roles in enhancing bone metastasis. Tumor cells localize to specific tissues through integrin-mediated contacts with extracellular matrix and stromal cells. Integrin expression and signaling are perturbed in cancer cells, allowing them to "escape" from cell-cell and cell-matrix tethers, invade, migrate and colonize within new tissues and matrices. Integrin signaling through alpha v beta 3 and VLA-4 on tumor cells can promote tumor metastasis to and proliferation in the bone microenvironment. Osteoclast (OC) mediated bone resorption is a critical component of bone metastasis and can promote tumor growth in bone and alpha v beta 3 integrins are critical to OC function and development. Tumors in the bone microenvironment can recruit new blood vessel formation, platelets, pro-tumor immune cells and bone marrow stromal cells that promote tumor growth and invasion in bone. Integrins and their ligands play critical roles in platelet aggregation (alpha v beta 3 and alpha llb beta 3), hematopoietic cell mobilization (VLA-4 and osteopontin), neoangiogenesis (alpha v beta 3,alpha v beta 5, alpha 6 beta 4, and beta 1 integrin) and stromal function (osteopontin and VLA-4). Integrins are involved in the pathogenesis of bone metastasis at many levels and further study to define integrin dysregulation by cancer will yield new therapeutic targets for the prevention and treatment of bone metastasis. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:54 / 65
页数:12
相关论文
共 290 条
[41]  
Chen Z G, 1988, Adv Exp Med Biol, V233, P61
[42]   Evidence of a colocalisation of osteoprotegerin (OPG) with von Willebrand factor (VWF) in platelets and megakaryocytes alpha granules. Studies from normal and grey platelets [J].
Chollet, Maria-Eugenia ;
Brouland, Jean-Philippe ;
Sollier, Claire Bal Dit ;
Bauduer, Frederic ;
Drouet, Ludovic ;
Bellucci, Sylvia .
BRITISH JOURNAL OF HAEMATOLOGY, 2010, 148 (05) :805-807
[43]   Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization [J].
Christopher, Matthew J. ;
Liu, Fulu ;
Hilton, Matthew J. ;
Long, Fanxin ;
Link, Daniel C. .
BLOOD, 2009, 114 (07) :1331-1339
[44]   Integrin (α6β4) regulation of eIF-4E activity and VEGF translation:: a survival mechanism for carcinoma cells [J].
Chung, J ;
Bachelder, RE ;
Lipscomb, EA ;
Shaw, LM ;
Mercurio, AM .
JOURNAL OF CELL BIOLOGY, 2002, 158 (01) :165-174
[45]   Integrins in Bone Metastasis Formation and Potential Therapeutic Implications [J].
Clezardin, P. .
CURRENT CANCER DRUG TARGETS, 2009, 9 (07) :801-806
[46]  
Clines Gregory A., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000616
[47]   Osteoclasts are required for bone tumors to grow and destroy bone [J].
Clohisy, DR ;
Ramnaraine, ML .
JOURNAL OF ORTHOPAEDIC RESEARCH, 1998, 16 (06) :660-666
[48]   Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid [J].
Coleman, RE ;
Major, P ;
Lipton, A ;
Brown, JE ;
Lee, KA ;
Smith, M ;
Saad, F ;
Zheng, M ;
Hei, YJ ;
Seaman, J ;
Cook, R .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :4925-4935
[49]   Metastatic bone disease: clinical features, pathophysiology and treatment strategies [J].
Coleman, RE .
CANCER TREATMENT REVIEWS, 2001, 27 (03) :165-176
[50]   Advancing Treatment for Metastatic Bone Cancer: Consensus Recommendations from the Second Cambridge Conference [J].
Coleman, Robert E. ;
Guise, Theresa A. ;
Lipton, Allan ;
Roodman, G. David ;
Berenson, James R. ;
Body, Jean-Jacques ;
Boyce, Brendan F. ;
Calvi, Laura M. ;
Hadji, Peyman ;
McCloskey, Eugene V. ;
Saad, Fred ;
Smith, Matthew R. ;
Suva, Larry J. ;
Taichman, Russell S. ;
Vessella, Robert L. ;
Weilbaecher, Katherine N. .
CLINICAL CANCER RESEARCH, 2008, 14 (20) :6387-6395